A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes

Journal of Pain and Symptom Management

Volumn 47, Issue 4, 2014, Pages

  Zeppetella, Giovambattista ^a   Davies, Andrew ^b   Eijgelshoven, Indra ^c   Jansen, Jeroen P ^d,e  

^a St Clare Hospice   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c MAPI GROUP   (Netherlands)

^d Mapi Group   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesia; breakthrough cancer pain; fentanyl; morphine; network meta analysis; randomized controlled trial

Indexed keywords

FENTANYL; FENTANYL CITRATE; MORPHINE SULFATE; NOSE SPRAY; OPIATE; PECTIN; PLACEBO; NARCOTIC ANALGESIC AGENT;

AEROSOL; ANALGESIA; ARTICLE; BREAKTHROUGH CANCER PAIN; BREAKTHROUGH PAIN; CANCER PAIN; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TABLET; NEOPLASM; PATHOPHYSIOLOGY;

ANALGESICS, OPIOID; BREAKTHROUGH PAIN; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898782233     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2013.05.020     Document Type: Review

References (56)

1. K. Lemay, K.G. Wilson, and U. Buenger et al. Fear of pain in patients with advanced cancer or in patients with chronic noncancer pain Clin J Pain 27 2011 116 124
2. D. Schrijvers Pain control in cancer: recent findings and trends Ann Oncol 18 Suppl 9 2007 ix37 ix42
3. B.R. Ferrell, G. Juarez, and T. Borneman Use of routine and breakthrough analgesia in home care Oncol Nurs Forum 26 1999 1655 1661
4. A.N. Davies, A. Dickman, C. Reid, A.M. Stevens, and G. Zeppetella The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain 13 2009 331 338
5. M.A. Simmonds Management of breakthrough pain due to cancer Oncology (Williston Park) 13 1999 1103 1108
6. R.K. Portenoy, and N.A. Hagen Breakthrough pain: definition, prevalence and characteristics Pain 41 1990 273 281
7. R.K. Portenoy, D. Payne, and P. Jacobsen Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1999 129 134
8. X. Gómez-Batiste, F. Madrid, and F. Moreno et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain J Pain Symptom Manage 24 2002 45 52
9. A. Davies, G. Zeppetella, and S. Andersen et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies Eur J Pain 15 2011 756 763
10. A. Caraceni, C. Martini, E. Zecca, and R.K. Portenoy Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey Palliat Med 18 2004 177 183
11. S.K. Reddy, and P. Nguyen Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge Curr Rev Pain 4 2000 242 247
12. B.V. Fortner, T.A. Okon, and R.K. Portenoy A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain J Pain 3 2002 38 44
13. B.V. Fortner, G. Demarco, and G. Irving et al. Description and predictors of direct and indirect costs of pain reported by cancer patients J Pain Symptom Manage 25 2003 9 18
14. A.P. Abernethy, J.L. Wheeler, and B.V. Fortner A health economic model of breakthrough pain Am J Manag Care 14 Suppl 1 2008 S129 S140
15. K. Mystakidou, I. Panagiotou, and A. Gouliamos Fentanyl nasal spray for the treatment of cancer pain Expert Opin Pharmacother 12 2011 1653 1659
16. S. Mercadante, L. Radbruch, and A. Caraceni et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care Cancer 94 2002 832 839
17. D. Bennett, A.W. Burton, and S. Fishman et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 Manage Pharm Ther 30 2005 354 361
18. A. Caraceni, G. Hanks, S. Kaasa European Palliative Care Research Collaboration (EPCRC) on behalf of the European Association for Palliative Care (EAPC) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC Lancet Oncol 13 2012 e58 e68
19. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
20. D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 897 900
21. J.P. Jansen, R. Fleurence, and B. Devine et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 2011 417 428
22. A. Cipriani, T.A. Furukawa, and G. Salanti et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
23. P. van de Kerkhof, R. de Peuter, J. Ryttov, and J.P. Jansen Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris Curr Med Res Opin 27 2011 225 238
24. B.M. Psaty, T. Lumley, and C.D. Furberg et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis JAMA 289 2003 2534 2544
25. N.J. Cooper, A.J. Sutton, G. Lu, and K. Khunti Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation Arch Intern Med 166 2006 1269 1275
26. G.G. Biondi-Zoccai, P. Agostoni, and A. Abbate et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials Int J Cardiol 100 2005 119 123
27. D. Vissers, W. Stam, T. Nolte, M. Lenre, and J. Jansen Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer Curr Med Res Opin 26 2010 1037 1045
28. A.R. Jadad, R.A. Moore, and D. Carroll et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
29. J.T. Farrar, R.K. Portenoy, J.A. Berlin, J.L. Kinman, and B.L. Strom Defining the clinically important difference in pain outcome measures Pain 88 2000 287 294
30. J.T. Farrar, J.A. Berlin, and B.L. Strom Clinically important changes in acute pain outcome measures: a validation study J Pain Symptom Manage 25 2003 406 411
31. J.P. Jansen, B. Crawford, G. Bergman, and W. Stam Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 2008 956 964
32. D.C. Hoaglin, N. Hawkins, and J.P. Jansen et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2 Value Health 14 2011 429 437
33. D.J. Spiegelhalter, N.G. Best, B.P. Carlin, and A. van der Linde Bayesian measures of model complexity and fit J R Stat Soc Series B Stat Methodol 64 2002 583 639
34. D. Spiegelhalter, A. Thomas, N. Best, and D. Lunn WinBUGS user manual: Version 1.4 2003 MRC Biostatistics Unit Cambridge, UK
35. H.G. Kress, A. Orońska, and Z. Kaczmarek et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period Clin Ther 31 2009 1177 1191
36. N.E. Slatkin, F. Xie, J. Messina, and T.J. Segal Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain J Support Oncol 5 2007 327 334
37. R.K. Portenoy, D. Taylor, J. Messina, and L. Tremmel A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 2006 805 811
38. J.T. Farrar, J. Cleary, R. Rauck, M. Busch, and E. Nordbrock Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 1998 611 616
39. S. Mercadante, L. Radbruch, and A. Davies et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial Curr Med Res Opin 25 2009 2805 2815
40. P.H. Coluzzi, L. Schwartzberg, and J.D. Conroy et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain 91 2001 123 130
41. R.K. Portenoy, A.W. Burton, N. Gabrail, and D. Taylor A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 2010 617 624
42. R.L. Rauck, M. Tark, and E. Reyes et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2009 2877 2885
43. R. Rauck, J. North, L.N. Gever, I. Tagarro, and A.L. Finn Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study Ann Oncol 21 2010 1308 1314
44. M. Fallon, A. Gatti, and A. Davies et al. Efficacy, safety and patient acceptability of fentanyl pectin spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, double-blind, double-dummy, multiple-crossover study Eur J Cancer Suppl 7 2009 15 [abstract 29LBA]
45. J.M. Christie, M. Simmonds, and R. Patt et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 1998 3238 3245
46. R.K. Portenoy, R. Payne, and P. Coluzzi et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study Pain 79 1999 303 312
47. A. Davies, T. Sitte, and F. Elsner et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain J Pain Symptom Manage 41 2011 358 366
48. M. Fallon, C. Reale, and A. Davies et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, randomised, controlled, double-blind, double-dummy, multiple-crossover study J Support Oncol 9 2011 224 231
49. J.B. Streisand, J.R. Varvel, and D.R. Stanski et al. Absorption and bioavailability of oral transmucosal fentanyl citrate Anesthesiology 75 1991 223 229
50. S.L. Collins, C.C. Faura, R.A. Moore, and H.J. McQuay Peak plasma concentrations after oral morphine: a systematic review J Pain Symptom Manage 16 1998 388 402
51. G. Hanks Oral transmucosal fentanyl citrate for the management of breakthrough pain Eur J Palliat Care 8 2001 6 9
52. M. Darwish, M. Kirby, P. Robertson, W. Tracewell, and J.G. Jiang Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study Clin Drug Investig 27 2007 605 611
53. S. Kaasa, K. Moksnes, and T. Nolte et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain J Opioid Manag 6 2010 17 26
54. D.C. Vissers, M. Lenre, and K. Tolley et al. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer Value Health 14 2011 274 281
55. J.P. Jansen, C.H. Schmid, and G. Salanti Direct acyclic graphs can help understand bias in indirect and mixed treatment comparisons J Clin Epidemiol 65 2012 798 807
56. G. Zeppetella, and M.D. Ribeiro Opioids for the management of breakthrough (episodic) pain in cancer patients Cochrane Database Syst Rev 1 2006 CD004311